Bio-Rad Laboratories, Inc. (NYSE:BIO) Stock Position Boosted by Harbor Capital Advisors Inc.

Harbor Capital Advisors Inc. grew its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 15.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,071 shares of the medical research company's stock after buying an additional 1,247 shares during the quarter. Harbor Capital Advisors Inc.'s holdings in Bio-Rad Laboratories were worth $2,209,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of BIO. Metis Global Partners LLC boosted its stake in shares of Bio-Rad Laboratories by 4.4% in the fourth quarter. Metis Global Partners LLC now owns 712 shares of the medical research company's stock valued at $234,000 after purchasing an additional 30 shares during the period. Signaturefd LLC boosted its stake in shares of Bio-Rad Laboratories by 13.2% in the fourth quarter. Signaturefd LLC now owns 265 shares of the medical research company's stock valued at $87,000 after purchasing an additional 31 shares during the period. Thrivent Financial for Lutherans boosted its stake in shares of Bio-Rad Laboratories by 0.7% in the fourth quarter. Thrivent Financial for Lutherans now owns 4,530 shares of the medical research company's stock valued at $1,488,000 after purchasing an additional 32 shares during the period. CIBC Asset Management Inc boosted its stake in shares of Bio-Rad Laboratories by 5.0% in the fourth quarter. CIBC Asset Management Inc now owns 713 shares of the medical research company's stock valued at $234,000 after purchasing an additional 34 shares during the period. Finally, Picton Mahoney Asset Management boosted its stake in shares of Bio-Rad Laboratories by 55.6% in the fourth quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company's stock valued at $32,000 after purchasing an additional 35 shares during the period. 65.24% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. UBS Group decreased their target price on shares of Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Royal Bank of Canada cut their price target on shares of Bio-Rad Laboratories from $409.00 to $392.00 and set an "outperform" rating on the stock in a report on Friday, May 2nd. Wall Street Zen cut shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a report on Sunday, June 8th. Wells Fargo & Company cut their price target on shares of Bio-Rad Laboratories from $260.00 to $245.00 and set an "equal weight" rating on the stock in a report on Monday, June 9th. Finally, Citigroup cut their price target on shares of Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $324.25.

Bio-Rad Laboratories Stock Performance

Shares of Bio-Rad Laboratories stock traded down $4.99 during trading on Friday, hitting $227.43. 452,343 shares of the stock were exchanged, compared to its average volume of 330,283. The stock's fifty day moving average is $236.37 and its 200 day moving average is $281.31. The stock has a market cap of $6.19 billion, a PE ratio of -3.50 and a beta of 0.93. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.85 and a current ratio of 6.48. Bio-Rad Laboratories, Inc. has a 12 month low of $211.43 and a 12 month high of $387.99.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical research company reported $2.54 EPS for the quarter, topping the consensus estimate of $1.73 by $0.81. The business had revenue of $585.40 million during the quarter, compared to analyst estimates of $573.01 million. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. The company's quarterly revenue was down 4.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.30 earnings per share. As a group, sell-side analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.